Standigm
Seoul, KR · 3 known investors
Find your way into Standigm
500 people in our graph share verified history with the Standigm team — schools, employers, funds. One of them is your warm intro.
Standigm is a Seoul-based AI drug discovery company offering target identification, lead optimization and AI SaaS/API services.
Also known as Standigm, Inc.
Founders & leadership
Investors · 3
Funding
SEC filings, press & company announcements$44.5M disclosed across 1 of 2 rounds · 2021
- $44.5MPre-IPOMar 2021 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026Standigm, Inc. is a South Korean artificial-intelligence drug discovery company headquartered in Seoul (Gangnam-gu). It applies workflow AI across the early drug discovery process, from first-in-class target identification through lead generation and optimization to preclinical candidate stages. Its stated proprietary platforms include Standigm ASK for target discovery, Standigm BEST for lead design, Standigm Insight for drug repurposing, and DarkMolFactory for automated molecular design; AI SaaS and API products STELLA and SPICA are described for target identification and optimization tasks.
The company positions itself in the AI-enabled small-molecule discovery segment, with reported therapeutic activity in oncology, and describes reducing average material optimization time from roughly 4.5 years to about 1.5 years and producing first-in-class lead compounds within about seven months. Its website markets an early-access offer of 1,000 generated molecule ideas for a given target within one week, alongside a two-week free trial of its AI tools limited to a set number of participants.
Third-party profiles classify Standigm under pharmaceutical manufacturing and healthcare IT with sub-industries spanning bioinformatics, pharmaceutical R&D and medical software, and record a Series B company stage.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 7
launches, deals, and filingsStandigm was included in a Gartner report as one of five companies highlighted as Tech Innovators in the generative AI in drug discovery use case.
Following three consecutive years of selection as a Top 100 AI company representing Korea, Standigm was nominated as a "Graduate" company through the 2023 Korea AI Startup 100 Colloquium and KT open AI-startup selection project.
Standigm was reported to be targeting an initial public offering in 2024 after shelving earlier plans to go public in 2021.
Standigm launched the "Green Ribbon Campaign" event in Seoul to support Mitochondrial Disease Awareness Week, held September 18-24, 2023.
Standigm entered a collaboration with Nashville Biosciences, LLC to accelerate early-stage drug discovery.
TSD Life Sciences signed a memorandum of understanding with Standigm to develop new small-molecule anticancer drugs.
Standigm announced the appointment of Younsung Choo as Chief Executive Officer.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 6
primary sources listed
- Standigmstandigm.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Standigm do?
- Standigm is a Seoul-based AI drug discovery company offering target identification, lead optimization and AI SaaS/API services.
- Who founded Standigm?
- Standigm was founded by Jinhan Kim, Sang Ok Song.
- Who are Standigm's investors?
- Standigm's investors include Atinum Investment Co. Ltd., Kakao Ventures, LB Investment.
- How much funding has Standigm raised?
- Standigm has disclosed $44.5M raised across 1 of its 2 known rounds.
- Where is Standigm headquartered?
- Standigm is headquartered in Seoul, KR.